ETF Series Solutions Trust Range Cancer Therapeutics ETF
CNCR
CNCR was delisted on the 27th of May, 2025.
15 hedge funds and large institutions have $8.44M invested in ETF Series Solutions Trust Range Cancer Therapeutics ETF in 2023 Q1 according to their latest regulatory filings, with 0 funds opening new positions, 2 increasing their positions, 7 reducing their positions, and 4 closing their positions.
0.79% more ownership
Funds ownership: 47.76% → 48.55% (+0.79%)
13% less capital invested
Capital invested by funds: $9.66M → $8.44M (-$1.22M)
25% less funds holding
Funds holding: 20 → 15 (-5)
71% less repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 7
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 4
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BL
BCWM LLC
Overland Park,
Kansas
|
+$352K |
| 2 |
Citadel Advisors
Miami,
Florida
|
+$169K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$307K |
| 2 |
CG
Colony Group
Boston,
Massachusetts
|
-$242K |
| 3 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
-$43.5K |
| 4 |
UBS Group
Zurich,
Switzerland
|
-$17.2K |
| 5 |
Morgan Stanley
New York
|
-$11.7K |
CNCR Hedge Fund Activity: Q1 2023 in Review
15 of the 6,276 institutional investors tracked by Wall St. Rank reported a position in ETF Series Solutions Trust Range Cancer Therapeutics ETF (CNCR) for Q1 2023, worth a combined $8.44M — down 13% from $9.66M a quarter earlier.
Sellers outnumbered buyers: 4 funds closed out of CNCR and 0 opened new positions — a net loss of 4 holders — while 7 trimmed existing stakes and 2 added.
The largest buyer was BCWM LLC, adding an estimated $352K. The largest seller was Susquehanna International Group, cutting an estimated $307K.
- 15 institutional investors held ETF Series Solutions Trust Range Cancer Therapeutics ETF (CNCR) as of Q1 2023, down from 20 in Q4 2022.
- Funds reported $8.44M of ETF Series Solutions Trust Range Cancer Therapeutics ETF stock for Q1 2023, down 13% quarter-over-quarter.
- 0 funds opened new ETF Series Solutions Trust Range Cancer Therapeutics ETF positions in Q1 2023 and 4 closed out, a net change of -4 holders.
- The largest ETF Series Solutions Trust Range Cancer Therapeutics ETF buyer in Q1 2023 was BCWM LLC, an estimated $352K added.
- The largest ETF Series Solutions Trust Range Cancer Therapeutics ETF seller in Q1 2023 was Susquehanna International Group, an estimated $307K sold.
Based on aggregated 13F filings for Q1 2023.